Overview:

Summary

The industry analysis specialist’s new report, “Dystonia - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global dystonia market. The report identifies the key trends shaping and driving the global dystonia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dystonia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global dystonia market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global dystonia market. Key players covered include Mentor Corporation and The National Institute of Neurological Disorders and Stroke (NINDS).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with dystonia.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dystonia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global dystonia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dystonia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Mentor Corporation
The National Institute of Neurological Disorders and Stroke (NINDS)

1 Table of contents
1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Dystonia: Market Characterization 5
2.1 Overview 5
2.2 Dystonia Market Size 5
2.3 Dystonia Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Dystonia Market 7
2.4.1 Drivers for the Dystonia market 7
2.4.2 Barriers for the Dystonia market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Dystonia Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the Dystonia Market 11
3.3.1 BOTOX (onabotulinumtoxinA) 11
3.3.2 DYSPORT (abobotulinumtoxinA) 12
3.3.3 MYOBLOC (rimabotulinumtoxinB) 12
3.3.4 Xeomin (NT-201) (botulinum neurotoxin type A) 13
3.4 Key Takeaway 15
4 Dystonia Market: Pipeline Assessment 16
4.1 Overview 16
4.2 Strategic Pipeline Assessment 16
4.2.1 Technology Trends Analytic Framework 16
4.3 Dystonia Therapeutics – Promising Drugs under Clinical Development 17
4.4 Molecule Profile for Promising Drugs under Clinical Development 17
4.4.1 PurTox (Mentor Corporation) 17
4.4.2 Amlodipine + BTX (National Institute of Neurological Disorders and Stroke) 18
4.5 Dystonia Therapeutics Market – Clinical Pipeline by Mechanism of Action 18
4.5.1 Dystonia Pipeline – Pipeline by Clinical Phases of Development 19
4.5.2 Dystonia Therapeutics – Phase II Clinical Pipeline 20
4.5.3 Dystonia Therapeutics – Phase I Clinical Pipeline 20
4.6 Key Takeaway 20
5 Dystonia Market: Implications for Future Market Competition 21
6 Dystonia Market: Future Players in the Dystonia Market 22
6.1 Introduction 22
6.2 Mentor Corporation, the US 22
6.2.1 Overview 22
6.2.2 Movement Disorders’ Portfolio 23
6.3 National Institute of Neurological Disorders and Stroke, the US 23
6.3.1 Overview 23
6.3.2 Movement Disorders’ Portfolio 24
7 Dystonia Market: Appendix 25
7.1 Definitions 25
7.2 Acronyms 25
7.3 Research Methodology 25
7.3.1 Coverage 26
7.3.2 Secondary Research 26
7.3.3 Forecasting 27
7.3.4 Primary Research 29
7.3.5 Expert Panel Validation 30
7.4 Contact Us 30
7.5 Disclaimer 30
7.6 Sources 30

1.1 List of Tables
Table 1: Dystonia Market Revenues ($m), Global, 2001–09 6
Table 2: Dystonia Market Forecast ($m), Global, 2009-2016 7
Table 3: Major Marketed Products Comparison in the Dystonia Market, 2010 15
Table 4: Dystonia Therapeutics – Most Promising Drugs Under Clinical Development, 2010 17
Table 5: Dystonia Therapeutics – Phase II Clinical Pipeline, 2010 20
Table 6: Dystonia Therapeutics – Phase I Clinical Pipeline, 2010 20
Table 7: Mentor Corporation – Dystonia Pipeline Products, 2010 23
Table 8: NINDS – Dystonia Pipeline Products, 2010 24

1.2 List of Figures
Figure 1: Dystonia Market Revenues ($m), Global, 2001–2009 6
Figure 2: Dystonia Market Forecast ($m), Global, 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Dystonia Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Marketed Products for Dystonia, 2010 10
Figure 5: Technology Trends Analytic Framework of the Dystonia Pipeline, 2010 16
Figure 6: Technology Trends Analytic Framework of the Dystonia Pipeline – Description, 2010 17
Figure 7: Dystonia Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 19
Figure 8: Dystonia Pipeline by Phase of Clinical Development, 2010 19
Figure 9: Implications for Future Market Competition in the Dystonia Market, 2010 21
Figure 10: Dystonia Market – Clinical Pipeline by Company, 2010 22
Figure 11: GlobalData Methodology 26
Figure 12: GlobalData Market Forecasting Model 29